- Home
- WHWK vs STRO Comparison
WHWK vs STRO Comparison
Compare WHWK & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | STRO |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 85.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WHWK | STRO |
|---|---|---|
| Price | $2.72 | $14.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $18.88 |
| AVG Volume (30 Days) | 108.0K | ★ 126.1K |
| Earning Date | 02-24-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,384,000.00 | ★ $105,646,000.00 |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $5.23 |
| 52 Week High | $3.77 | $21.25 |
Technical Indicators
Market Signals| Indicator | WHWK | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 62.95 |
| Support Level | $2.60 | $14.08 |
| Resistance Level | $2.83 | $16.91 |
| Average True Range (ATR) | 0.19 | 1.50 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 41.47 | 67.25 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.